Lead Product(s): Imatinib Mesylate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Post-dose vision in all YD-312 dose groups compared with pre-dose was statistically significant, visual acuity was maintained, or the treatment efficiency improved significantly compared to the placebo group, the official noted.